Neonatal enteroviral sepsis (NES) is a severe enterovirus (EV) infection in the neonate that may manifest with serious complications such as hepatic necrosis, coagulopathy, and myocarditis. Currently no U.S. Food and Drug Administration (FDA) approved drug product exists for the treatment of NES, although reports indicate intravenous immune globulin (IVIG) is sometimes administered. FDA required observational data on NES prevalence and mortality rates to inform the design of future clinical trials to evaluate investigational new drugs for NES treatment. The objective of this project is to describe NES prevalence and mortality rates among hospitalized neonates in the Sentinel System.